Since more EGFR TKIs, including Erlotinib, Afatinib, Dacomitinib, and Osimertinib, have been developed in this decade, the survival rate of NSCLC patients has greatly improved in recent years worldwide [6,7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.